Cacipliq 20®

Cacipliq 20® is a class III medical device dedicated to wound healing. It is the first product incorporating our innovative RGTA® technology.

Contraindications and warnings exist. Please follow instructions in the package insert. You may read Instructions For Use clicking the link below.

Cacipliq20, dispositif médical pour l'homme

Further information on Cacipliq 20®

Cacipliq 20® is based on the Regenerating Agents family (RGTA®) which consist of modified biodegradable sugars.

It protects extracellular matrix proteins, helping to restore their original structure, preserving the natural cellular microenvironment of the wound as well as the endogenous factors necessary for tissue regeneration.

Supplied as sterile solution for easy application twice a week, it facilitates rapid and efficacious wound healing. Cacipliq 20® is a unique product that provides an effective and easy-to-use tissue regeneration solution proven to accelerate the healing of wounds, even those associated with chronic resistant ulcers such as those found in diabetes.

For chronic ulcers showing no tendency to heal after 6 months of conventional care, or untreated ulcers after 12 months including :

  • Bedsores
  • Ulcers following peripheral arterial disease (such as Leriche & Fontaine stage 4)
  • Diabetic ulcers (including amputation)
  • Sterile solution for external use.
  • Spray: box containing a 7.5 ml bottle: around 50 pushes, 3K® pump guaranteeing sterility for 6 months.
  • Kit: 5 ml vial with sterile compress, 2 per box.
  • Preservative free.
  • Reduced healing time
  • Excellent product safety history
  • Easy to use


The effectiveness of Cacipliq20® has been demonstrated by three clinical trials and numerous case studies.
Below you will find a selection of clinical publications featuring our product.

  • Cacipliq 20

    Cacipliq 20® - Ischemic wound First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA ® ) technology P. DESGRANGES, T. LOUISSAINT, E. ALLAIRE, B. GODEAU, K. KICHENIN, J.- P. BECQUEMIN, D. BARRITAULT Patients with non-healing leg ulcers due to severe limb ischemia and [...]

  • Cacipliq 20

    Cacipliq 20® - Chronic wound Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study Groah SL, Libin A, Spungen M, Nguyen KL, Woods E, Nabili M, Ramella-Roman J, Barritault D. The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan [...]

  • Cacipliq 20

    Cacipliq 20® - Post radiation Unexpected healing of radiation-induced scalp lesions with OTR4120, an heparan sulfate mimetic Johan W VAN NECK ,Yolinde S. ZUIDEMA, Marijke SMULDERS, Kurt J. BALMUS Link : Here

Questions about OTR3 ?